Table 9.
Pairwise meta-analysis of VEGFR-TKIs’ cardiac event
| Direct compare | Study number | Total sample | Odds ratio (95% CI) | Method | Heterogeneity |
|---|---|---|---|---|---|
| Suntinib vs placebo | 2 | 1416 | 1.37(0.65,2.88) | M–H random | I2 = 0% (P = 0.38) |
| Sorafenib vs placebo | 5 | 4278 | 2.12 (0.86,5.19) | M–H Random | I2 = 40% (P = 0.16) |
| Regorafenib vs placebo | 3 | 583 | 1.16 (0.24,5.63) | M–H random | I2 = 43% (P = 0.18) |
| Vandetanib vs placebo | 5 | 1619 | 15.01 (4.66, 48.37) | M–H random | I2 = 0% (P = 0.92) |
| Pazopanib vs placebo | 4 | 1943 | 6.67(1.98,22.51) | M–H random | I2 = 0% (P = 0.73) |
| Nintedanib vs sorafenib | 2 | 188 | 0.31(0.04,2.56) | M–H random | I2 = 0% (P = 0.62) |